{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:57:15Z","timestamp":1794434235070,"version":"4.9.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41584-026-01391-5","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:22:30Z","timestamp":1781511750000},"page":"496-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6844","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Gunkl-T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-5879","authenticated-orcid":false,"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3228","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"1391_CR1","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1093\/bioinformatics\/bty357","volume":"34","author":"K Sechidis","year":"2018","unstructured":"Sechidis, K. et al. Distinguishing prognostic and predictive biomarkers: an information theoretic approach. Bioinformatics 34, 3365\u20133376 (2018).","journal-title":"Bioinformatics"},{"key":"1391_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101812","volume":"36","author":"J Thomas","year":"2022","unstructured":"Thomas, J., Bansback, N., Barber, C., Wells, G. & Hazlewood, G. Personalized medicine in rheumatoid arthritis: combining biomarkers and patient preferences to guide therapeutic decisions. Best. Pract. Res. Clin. Rheumatol. 36, 101812 (2022).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1391_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/00045632241285843","volume":"62","author":"D Sahin","year":"2025","unstructured":"Sahin, D., Di Matteo, A. & Emery, P. Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: a comprehensive review. Ann. Clin. Biochem. 62, 3\u201321 (2025).","journal-title":"Ann. Clin. Biochem."},{"key":"1391_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semarthrit.2018.12.006","volume":"49","author":"IC Scott","year":"2019","unstructured":"Scott, I. C. et al. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life. Semin. Arthritis Rheum. 49, 20\u201326 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1391_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe, B. et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann. Rheum. Dis. 76, 948\u2013959 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados, M. et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 73, 62\u201368 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/annrheumdis-2016-209233","volume":"75","author":"A Baillet","year":"2016","unstructured":"Baillet, A. et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann. Rheum. Dis. 75, 965\u2013973 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR8","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205\u20132219 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1391_CR9","doi-asserted-by":"publisher","first-page":"SI271","DOI":"10.1093\/rheumatology\/kead352","volume":"62","author":"J Majnik","year":"2023","unstructured":"Majnik, J. & Nagy, G. Viewpoint: could better understanding of risk factors for comorbidities pave the way towards personalized therapy in rheumatoid arthritis? Rheumatology 62, SI271\u2013SI273 (2023).","journal-title":"Rheumatology"},{"key":"1391_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrrheum.2013.212","volume":"10","author":"H Radner","year":"2014","unstructured":"Radner, H., Yoshida, K., Smolen, J. S. & Solomon, D. H. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat. Rev. Rheumatol. 10, 252\u2013256 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580\u20131588 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105543","volume":"90","author":"AHM Van der Helm-van Mil","year":"2023","unstructured":"Van der Helm-van Mil, A. H. M. Preventive interventions in individuals at risk for rheumatoid arthritis: state of the art and perspectives. Jt. Bone Spine 90, 105543 (2023).","journal-title":"Jt. Bone Spine"},{"key":"1391_CR13","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/art.38097","volume":"65","author":"T Frisell","year":"2013","unstructured":"Frisell, T. et al. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor\/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 65, 2773\u20132782 (2013).","journal-title":"Arthritis Rheum."},{"key":"1391_CR14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-022-01213-w","volume":"54","author":"K Ishigaki","year":"2022","unstructured":"Ishigaki, K. et al. Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat. Genet. 54, 1640\u20131651 (2022).","journal-title":"Nat. Genet."},{"key":"1391_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/art.42323","volume":"75","author":"MP Maurits","year":"2023","unstructured":"Maurits, M. P. et al. The role of genetics in clinically suspect arthralgia and rheumatoid arthritis development: a large cross-sectional study. Arthritis Rheumatol. 75, 178\u2013186 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1391_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1548","volume":"12","author":"R Knevel","year":"2020","unstructured":"Knevel, R. et al. Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. Sci. Transl. Med. 12, eaay1548\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aay1548 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1391_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7861\/fhj.10-3-s24","volume":"10","author":"R Hum","year":"2023","unstructured":"Hum, R. et al. Harnessing genetics in the outpatient clinic using polygenic risk scores to aid diagnosis of patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Future Healthc. J. 10, 24\u201325 (2023).","journal-title":"Future Healthc. J."},{"key":"1391_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-023-00244-1","volume":"11","author":"X Peng","year":"2023","unstructured":"Peng, X. et al. Comprehensive overview of microRNA function in rheumatoid arthritis. Bone Res. 11, 8 (2023).","journal-title":"Bone Res."},{"key":"1391_CR19","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/annrheumdis-2012-202815","volume":"73","author":"M Filkova","year":"2014","unstructured":"Filkova, M. et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 73, 1898\u20131904 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-020-00199-7","volume":"26","author":"M Taha","year":"2020","unstructured":"Taha, M., Shaker, O. G., Abdelsalam, E. & Taha, N. Serum a proliferation-inducing ligand and MicroRNA-223 are associated with rheumatoid arthritis: diagnostic and prognostic implications. Mol. Med. 26, 92 (2020).","journal-title":"Mol. Med."},{"key":"1391_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087925","volume":"14","author":"Y Jiang","year":"2023","unstructured":"Jiang, Y. et al. Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis. Front. Immunol. 14, 1087925 (2023).","journal-title":"Front. Immunol."},{"key":"1391_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.autrev.2009.04.006","volume":"9","author":"P Szodoray","year":"2010","unstructured":"Szodoray, P. et al. Anti-citrullinated protein\/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun. Rev. 9, 140\u2013143 (2010).","journal-title":"Autoimmun. Rev."},{"key":"1391_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103421","volume":"23","author":"G Steiner","year":"2024","unstructured":"Steiner, G. et al. Should ACR\/EULAR criteria be revised changing the RF and ACPA scores? Autoimmun. Rev. 23, 103421 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1391_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura, K. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 146, 797\u2013808 (2007).","journal-title":"Ann. Intern. Med."},{"key":"1391_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","volume":"152","author":"PF Whiting","year":"2010","unstructured":"Whiting, P. F. et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann. Intern. Med. 152, 456\u2013464; W155\u2013W166 (2010).\u00a0","journal-title":"Ann. Intern. Med."},{"key":"1391_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380\u2013386 (2004).","journal-title":"Arthritis Rheum."},{"key":"1391_CR27","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741\u20132749 (2003).","journal-title":"Arthritis Rheum."},{"key":"1391_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001085","volume":"6","author":"A Finckh","year":"2020","unstructured":"Finckh, A., Courvoisier, D. & Lamacchia, C. Recherche clinique en rhumatismes inflammatoires. Measuring ACPA in the general population or primary care: is it useful? RMD Open 6, e001085\u00a0https:\/\/doi.org\/10.1136\/rmdopen-2019-001085 (2020).","journal-title":"RMD Open"},{"key":"1391_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2015-208980","volume":"76","author":"AH Hensvold","year":"2017","unstructured":"Hensvold, A. H. et al. How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. Ann. Rheum. Dis. 76, 119\u2013125 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"120288","DOI":"10.1016\/j.cca.2025.120288","volume":"574","author":"Y Yi","year":"2025","unstructured":"Yi, Y. et al. Biomarkers for early diagnosis of rheumatoid arthritis. Clin. Chim. Acta 574, 120288 (2025).","journal-title":"Clin. Chim. Acta"},{"key":"1391_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr8078","volume":"11","author":"Y Xie","year":"2025","unstructured":"Xie, Y. et al. Large-scale multicenter study reveals anticitrullinated SR-A peptide antibody as a biomarker and exacerbator for rheumatoid arthritis. Sci. Adv. 11, eadr8078 (2025).","journal-title":"Sci. Adv."},{"key":"1391_CR32","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/rheumatology\/keae297","volume":"64","author":"C Wei","year":"2025","unstructured":"Wei, C. et al. Combination of scavenger receptor-A with anti-cyclic citrullinated peptide antibody for the diagnosis of rheumatoid arthritis. Rheumatology 64, 1513\u20131522 (2025).","journal-title":"Rheumatology"},{"key":"1391_CR33","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl Acad. Sci. USA 108, 17372\u201317377 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1391_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0860-6","volume":"17","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res. Ther. 17, 339 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR35","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1136\/annrheumdis-2013-205109","volume":"73","author":"X Jiang","year":"2014","unstructured":"Jiang, X. et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann. Rheum. Dis. 73, 1761\u20131768 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05992-3","volume":"45","author":"P Nakaphan","year":"2025","unstructured":"Nakaphan, P. et al. Diagnostic accuracy of anti-carbamylated protein antibodies in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol. Int. 45, 232 (2025).","journal-title":"Rheumatol. Int."},{"key":"1391_CR37","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/annrheumdis-2014-206785","volume":"75","author":"M Juarez","year":"2016","unstructured":"Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099\u20131107 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627986","volume":"12","author":"C Gronwall","year":"2021","unstructured":"Gronwall, C. et al. A comprehensive evaluation of the relationship between different IgG and IgA anti-modified protein autoantibodies in rheumatoid arthritis. Front. Immunol. 12, 627986 (2021).","journal-title":"Front. Immunol."},{"key":"1391_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.intimp.2018.01.022","volume":"56","author":"TR Mikuls","year":"2018","unstructured":"Mikuls, T. R. et al. Malondialdehyde-acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions. Int. Immunopharmacol. 56, 113\u2013118 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"1391_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003480","volume":"9","author":"MD van den Beukel","year":"2023","unstructured":"van den Beukel, M. D. et al. Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open 9, e003480\u00a0https:\/\/doi.org\/10.1136\/rmdopen-2023-003480 (2023).","journal-title":"RMD Open"},{"key":"1391_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jvs.2014.08.117","volume":"63","author":"JS Carson","year":"2016","unstructured":"Carson, J. S. et al. Antibodies against malondialdehyde-acetaldehyde adducts can help identify patients with abdominal aortic aneurysm. J. Vasc. Surg. 63, 477\u2013484 (2016).","journal-title":"J. Vasc. Surg."},{"key":"1391_CR42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/art.43149","volume":"77","author":"AM Wheeler","year":"2025","unstructured":"Wheeler, A. M. et al. Peripheral biomarker signatures in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 77, 971\u2013980 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"1391_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-020-0409-1","volume":"16","author":"AM Curran","year":"2020","unstructured":"Curran, A. M., Naik, P., Giles, J. T. & Darrah, E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat. Rev. Rheumatol. 16, 301\u2013315 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR44","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3899\/jrheum.080770","volume":"36","author":"T Sokka","year":"2009","unstructured":"Sokka, T. & Pincus, T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%\u201345% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J. Rheumatol. 36, 1387\u20131390 (2009).","journal-title":"J. Rheumatol."},{"key":"1391_CR45","first-page":"1477","volume":"24","author":"F Wolfe","year":"1997","unstructured":"Wolfe, F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J. Rheumatol. 24, 1477\u20131485 (1997).","journal-title":"J. Rheumatol."},{"key":"1391_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-368","volume":"15","author":"L Siemons","year":"2014","unstructured":"Siemons, L. et al. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet. Disord. 15, 368 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1391_CR47","first-page":"58","volume":"27","author":"G Cunnane","year":"2000","unstructured":"Cunnane, G. et al. Serum amyloid A in the assessment of early inflammatory arthritis. J. Rheumatol. 27, 58\u201363 (2000).","journal-title":"J. Rheumatol."},{"key":"1391_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103295","volume":"22","author":"M Manfredi","year":"2023","unstructured":"Manfredi, M. et al. Circulating calprotectin (cCLP) in autoimmune diseases. Autoimmun. Rev. 22, 103295 (2023).","journal-title":"Autoimmun. Rev."},{"key":"1391_CR49","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3899\/jrheum.131446","volume":"41","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych, W. P. et al. Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J. Rheumatol. 41, 2104\u20132113 (2014).","journal-title":"J. Rheumatol."},{"key":"1391_CR50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.berh.2019.01.010","volume":"32","author":"O Shovman","year":"2018","unstructured":"Shovman, O. et al. The diagnostic value of 14-3-3\u03b7 protein levels in patients with rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol. 32, 610\u2013617 (2018).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1391_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-023-00966-w","volume":"19","author":"B Grillet","year":"2023","unstructured":"Grillet, B. et al. Matrix metalloproteinases in arthritis: towards precision medicine. Nat. Rev. Rheumatol. 19, 363\u2013377 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR52","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/annrheumdis-2020-217215","volume":"79","author":"A Di Matteo","year":"2020","unstructured":"Di Matteo, A. et al. Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis. Ann. Rheum. Dis. 79, 901\u2013907 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051735","volume":"14","author":"M Colina","year":"2025","unstructured":"Colina, M. & Campana, G. Precision medicine in rheumatology: the role of biomarkers in diagnosis and treatment optimization. J. Clin. Med. 14, 1735\u00a0https:\/\/doi.org\/10.3390\/jcm14051735 (2025).","journal-title":"J. Clin. Med."},{"key":"1391_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110594","volume":"26","author":"M Xue","year":"2025","unstructured":"Xue, M., Wang, H., Campos, F., Jackson, C. J. & March, L. Rheumatoid arthritis: biomarkers and the latest breakthroughs. Int. J. Mol. Sci. 26, 10594 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1391_CR55","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/rheumatology\/keae701","volume":"64","author":"JS Smolen","year":"2025","unstructured":"Smolen, J. S. Poor prognostic factors and unmet needs in rheumatoid arthritis. Rheumatology 64, ii3\u2013ii8 (2025).","journal-title":"Rheumatology"},{"key":"1391_CR56","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/00325481.2022.2052626","volume":"135","author":"D Abdelhafiz","year":"2023","unstructured":"Abdelhafiz, D., Baker, T., Glascow, D. A. & Abdelhafiz, A. Biomarkers for the diagnosis and treatment of rheumatoid arthritis \u2014 a systematic review. Postgrad. Med. 135, 214\u2013223 (2023).","journal-title":"Postgrad. Med."},{"key":"1391_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2025.102106","volume":"39","author":"T Gudu","year":"2025","unstructured":"Gudu, T., Oztas, M. & Nikiphorou, E. Contemporary approaches to the management of rheumatoid arthritis: precision and progress. Best. Pract. Res. Clin. Rheumatol. 39, 102106\u00a0https:\/\/doi.org\/10.1016\/j.berh.2025.102106 (2025).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1391_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010182","volume":"12","author":"B Frade-Sosa","year":"2022","unstructured":"Frade-Sosa, B. et al. High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or jak inhibitors: a clinical and ultrasonographic study. Diagnostics 12, 182 (2022).","journal-title":"Diagnostics"},{"key":"1391_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.12.011","volume":"52","author":"J Zhou","year":"2022","unstructured":"Zhou, J., Dai, Y., Lin, Y. & Chen, K. Association between serum amyloid A and rheumatoid arthritis: a systematic review and meta-analysis. Semin. Arthritis Rheum. 52, 151943 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"1391_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","volume":"42","author":"MJ Green","year":"2003","unstructured":"Green, M. J. et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42, 83\u201388 (2003).","journal-title":"Rheumatology"},{"key":"1391_CR61","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000490350","volume":"27","author":"SZ Prodanovic","year":"2018","unstructured":"Prodanovic, S. Z. et al. Matrix metalloproteinases-3 baseline serum levels in early rheumatoid arthritis patients without initial radiographic changes: a two-year ultrasonographic study. Med. Princ. Pract. 27, 378\u2013386 (2018).","journal-title":"Med. Princ. Pract."},{"key":"1391_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60121945","volume":"60","author":"V Smolinska","year":"2024","unstructured":"Smolinska, V., Klimova, D., Danisovic, L. & Harsanyi, S. Synovial fluid markers and extracellular vesicles in rheumatoid arthritis. Medicina 60, 1945 (2024).","journal-title":"Medicina"},{"key":"1391_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3899\/jrheum.080180","volume":"36","author":"SW Syversen","year":"2009","unstructured":"Syversen, S. W. et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J. Rheumatol. 36, 266\u2013272 (2009).","journal-title":"J. Rheumatol."},{"key":"1391_CR64","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/1529-0131(200201)46:1<21::AID-ART10061>3.0.CO;2-Q","volume":"46","author":"P Garnero","year":"2002","unstructured":"Garnero, P., Gineyts, E., Christgau, S., Finck, B. & Delmas, P. D. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum. 46, 21\u201330 (2002).","journal-title":"Arthritis Rheum."},{"key":"1391_CR65","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s12276-024-01188-0","volume":"56","author":"K-M Kim","year":"2024","unstructured":"Kim, K.-M. et al. The acute phase reactant orosomucoid-2 directly promotes rheumatoid inflammation. Exp. Mol. Med. 56, 890\u2013903 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1391_CR66","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera, G. et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann. Rheum. Dis. 78, 1642\u20131652 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR67","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis, M. J. et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 28, 2455\u20132470.e5 (2019).","journal-title":"Cell Rep."},{"key":"1391_CR68","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/rheumatology\/keu163","volume":"53","author":"S Bugatti","year":"2014","unstructured":"Bugatti, S. et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology 53, 1886\u20131895 (2014).","journal-title":"Rheumatology"},{"key":"1391_CR69","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2741\/s53","volume":"2","author":"Z Szekanecz","year":"2010","unstructured":"Szekanecz, Z., Vegvari, A., Szabo, Z. & Koch, A. E. Chemokines and chemokine receptors in arthritis. Front. Biosci. (Schol. Ed.) 2, 153\u2013167 (2010).","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"1391_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850998","volume":"13","author":"Z Pan","year":"2022","unstructured":"Pan, Z., Zhu, T., Liu, Y. & Zhang, N. Role of the CXCL13\/CXCR5 Axis in autoimmune diseases. Front. Immunol. 13, 850998 (2022).","journal-title":"Front. Immunol."},{"key":"1391_CR71","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","volume":"26","author":"S Alivernini","year":"2020","unstructured":"Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295\u20131306 (2020).","journal-title":"Nat. Med."},{"key":"1391_CR72","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/ard.60.10.924","volume":"60","author":"LM Jansen","year":"2001","unstructured":"Jansen, L. M., van der Horst-Bruinsma, I. E., van Schaardenburg, D., Bezemer, P. D. & Dijkmans, B. A. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 60, 924\u2013927 (2001).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR73","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/rheumatology\/keq437","volume":"50","author":"A Baillet","year":"2011","unstructured":"Baillet, A. et al. Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 50, 1137\u20131147 (2011).","journal-title":"Rheumatology"},{"key":"1391_CR74","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11547-019-01002-2","volume":"124","author":"E Filippucci","year":"2019","unstructured":"Filippucci, E. et al. Ultrasound imaging in rheumatoid arthritis. Radiol. Med. 124, 1087\u20131100 (2019).","journal-title":"Radiol. Med."},{"key":"1391_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02685-7","volume":"23","author":"J Molina Collada","year":"2021","unstructured":"Molina Collada, J. et al. Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development. Arthritis Res. Ther. 23, 299 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR76","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3899\/jrheum.161433","volume":"44","author":"M Ostergaard","year":"2017","unstructured":"Ostergaard, M. et al. The OMERACT rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in arthritis working group. J. Rheumatol. 44, 1706\u20131712 (2017).","journal-title":"J. Rheumatol."},{"key":"1391_CR77","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/ard.2008.088245","volume":"68","author":"ML Hetland","year":"2009","unstructured":"Hetland, M. L. et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann. Rheum. Dis. 68, 384\u2013390 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR78","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3899\/jrheum.140741","volume":"42","author":"DP de Rooy","year":"2015","unstructured":"de Rooy, D. P. et al. Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. J. Rheumatol. 42, 1383\u20131391 (2015).","journal-title":"J. Rheumatol."},{"key":"1391_CR79","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00011-017-1119-2","volume":"67","author":"C Addobbati","year":"2018","unstructured":"Addobbati, C. et al. Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients. Inflamm. Res. 67, 255\u2013264 (2018).","journal-title":"Inflamm. Res."},{"key":"1391_CR80","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00296-019-04344-2","volume":"39","author":"A Singh","year":"2019","unstructured":"Singh, A., Misra, R. & Aggarwal, A. Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis. Rheumatol. Int. 39, 1431\u20131438 (2019).","journal-title":"Rheumatol. Int."},{"key":"1391_CR81","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1007\/s10067-018-4268-y","volume":"37","author":"F Yeganeh","year":"2018","unstructured":"Yeganeh, F. et al. Association of CD26\/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis. Clin. Rheumatol. 37, 3183\u20133190 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1391_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01336","volume":"11","author":"A Lamana","year":"2020","unstructured":"Lamana, A. et al. Identification of a human SOCS1 polymorphism that predicts rheumatoid arthritis severity. Front. Immunol. 11, 1136 (2020).","journal-title":"Front. Immunol."},{"key":"1391_CR83","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3899\/jrheum.131412","volume":"41","author":"IM Markusse","year":"2014","unstructured":"Markusse, I. M. et al. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J. Rheumatol. 41, 2114\u20132119 (2014).","journal-title":"J. Rheumatol."},{"key":"1391_CR84","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1093\/rheumatology\/keac715","volume":"62","author":"FA Meznerics","year":"2023","unstructured":"Meznerics, F. A. et al. Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. Rheumatology 62, 2048\u20132059 (2023).","journal-title":"Rheumatology"},{"key":"1391_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1381272","volume":"15","author":"X Gong","year":"2024","unstructured":"Gong, X. et al. An overview of multi-omics technologies in rheumatoid arthritis: applications in biomarker and pathway discovery. Front. Immunol. 15, 1381272 (2024).","journal-title":"Front. Immunol."},{"key":"1391_CR86","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41584-026-01354-w","volume":"22","author":"L Gunkl-Toth","year":"2026","unstructured":"Gunkl-Toth, L., McInnes, I. B. & Nagy, G. Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis. Nat. Rev. Rheumatol. 22, 319\u2013327\u00a0https:\/\/doi.org\/10.1038\/s41584-026-01354-w (2026).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy, G. et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 80, 31\u201335 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR88","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier, D. S. et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology 60, 820\u2013828 (2021).","journal-title":"Rheumatology"},{"key":"1391_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000742","volume":"5","author":"P Bird","year":"2019","unstructured":"Bird, P. et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in phase III randomised clinical trials of tofacitinib. RMD Open 5, e000742 (2019).","journal-title":"RMD Open"},{"key":"1391_CR90","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/rheumatology\/keae113","volume":"64","author":"K Takase-Minegishi","year":"2025","unstructured":"Takase-Minegishi, K. et al. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology 64, 548\u2013560 (2025).","journal-title":"Rheumatology"},{"key":"1391_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04248-y","volume":"22","author":"A Juli\u00e0","year":"2021","unstructured":"Juli\u00e0, A. et al. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy. BMC Musculoskelet. Disord. 22, 372 (2021).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1391_CR92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.55563\/clinexprheumatol\/g8xqxr","volume":"39","author":"R Kumar","year":"2021","unstructured":"Kumar, R. et al. Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clin. Exp. Rheumatol. 39, 91\u201397 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1391_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0717-z","volume":"17","author":"L Lindenberg","year":"2015","unstructured":"Lindenberg, L. et al. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. Arthritis Res. Ther. 17, 206 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03470-y","volume":"27","author":"A Floris","year":"2025","unstructured":"Floris, A. et al. The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis. Arthritis Res. Ther. 27, 9 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR95","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","volume":"41","author":"Y Khader","year":"2022","unstructured":"Khader, Y., Beran, A., Ghazaleh, S., Lee-Smith, W. & Altorok, N. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin. Rheumatol. 41, 3615\u20133627 (2022).","journal-title":"Clin. Rheumatol."},{"key":"1391_CR96","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K Shimamoto","year":"2013","unstructured":"Shimamoto, K. et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J. Rheumatol. 40, 1074\u20131081 (2013).","journal-title":"J. Rheumatol."},{"key":"1391_CR97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/14397595.2013.854079","volume":"24","author":"N Nishimoto","year":"2014","unstructured":"Nishimoto, N. et al. Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study. Mod. Rheumatol. 24, 17\u201325 (2014).","journal-title":"Mod. Rheumatol."},{"key":"1391_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0799-7","volume":"17","author":"S Hirata","year":"2015","unstructured":"Hirata, S., Marotta, A., Gui, Y., Hanami, K. & Tanaka, Y. Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res. Ther. 17, 280 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR99","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10067-006-0520-y","volume":"26","author":"G Morozzi","year":"2007","unstructured":"Morozzi, G. et al. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin. Rheumatol. 26, 1335\u20131338 (2007).","journal-title":"Clin. Rheumatol."},{"key":"1391_CR100","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby, F. et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann. Rheum. Dis. 78, 761\u2013772 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR101","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305\u2013317 (2021).","journal-title":"Lancet"},{"key":"1391_CR102","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256\u20131268 (2022).","journal-title":"Nat. Med."},{"key":"1391_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60987-9","volume":"16","author":"MJ Lewis","year":"2025","unstructured":"Lewis, M. J. et al. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat. Commun. 16, 5374 (2025).","journal-title":"Nat. Commun."},{"key":"1391_CR104","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese, F. et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 5, e648\u2013e659 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1391_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15120622","volume":"15","author":"S Ketabchi","year":"2025","unstructured":"Ketabchi, S. et al. Biopsy-driven synovial pathophenotyping in RA: a new approach to personalized treatment. J. Pers. Med. 15, 622\u00a0https:\/\/doi.org\/10.3390\/jpm15120622 (2025).","journal-title":"J. Pers. Med."},{"key":"1391_CR106","first-page":"921","volume":"40","author":"F Ceccarelli","year":"2022","unstructured":"Ceccarelli, F. et al. The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors: results from a monocentric cohort. Clin. Exp. Rheumatol. 40, 921\u2013927 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1391_CR107","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/rheumatology\/keu217","volume":"53","author":"H Nguyen","year":"2014","unstructured":"Nguyen, H. et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology 53, 2110\u20132118 (2014).","journal-title":"Rheumatology"},{"key":"1391_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001511","volume":"7","author":"NM Roodenrijs","year":"2021","unstructured":"Roodenrijs, N. M. et al. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open 7, e001511 (2021).","journal-title":"RMD Open"},{"key":"1391_CR109","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1016\/S2665-9913(25)00032-3","volume":"7","author":"A Hess","year":"2025","unstructured":"Hess, A. et al. Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study. Lancet Rheumatol. 7, e565\u2013e575 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1391_CR110","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/art.37761","volume":"65","author":"J Rech","year":"2013","unstructured":"Rech, J. et al. Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis. Arthritis Rheum. 65, 325\u2013333 (2013).","journal-title":"Arthritis Rheum."},{"key":"1391_CR111","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/FPC.0000000000000036","volume":"24","author":"S Senapati","year":"2014","unstructured":"Senapati, S. et al. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet. Genomics 24, 211\u2013219 (2014).","journal-title":"Pharmacogenet. Genomics"},{"key":"1391_CR112","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10067-024-06892-w","volume":"43","author":"AM Nomair","year":"2024","unstructured":"Nomair, A. M. et al. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clin. Rheumatol. 43, 971\u2013983 (2024).","journal-title":"Clin. Rheumatol."},{"key":"1391_CR113","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41397-019-0098-9","volume":"20","author":"F Eektimmerman","year":"2020","unstructured":"Eektimmerman, F., Swen, J. J., Madhar, M. B., Allaart, C. F. & Guchelaar, H. J. Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. Pharmacogenomics J. 20, 159\u2013168 (2020).","journal-title":"Pharmacogenomics J."},{"key":"1391_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003394","volume":"9","author":"J Cui","year":"2013","unstructured":"Cui, J. et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 9, e1003394 (2013).","journal-title":"PLoS Genet."},{"key":"1391_CR115","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/art.27457","volume":"62","author":"J Cui","year":"2010","unstructured":"Cui, J. et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 62, 1849\u20131861 (2010).","journal-title":"Arthritis Rheum."},{"key":"1391_CR116","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.33381","volume":"64","author":"D Plant","year":"2012","unstructured":"Plant, D. et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 64, 665\u2013670 (2012).","journal-title":"Arthritis Rheum."},{"key":"1391_CR117","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/art.41885","volume":"73","author":"C de la Calle-Fabregat","year":"2021","unstructured":"de la Calle-Fabregat, C. et al. Prediction of the progression of undifferentiated arthritis to rheumatoid arthritis using DNA methylation profiling. Arthritis Rheumatol. 73, 2229\u20132239 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1391_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303231","volume":"14","author":"I Hageman","year":"2023","unstructured":"Hageman, I. et al. Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients. Front. Immunol. 14, 1303231 (2023).","journal-title":"Front. Immunol."},{"key":"1391_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05044-4","volume":"9","author":"S Tasaki","year":"2018","unstructured":"Tasaki, S. et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat. Commun. 9, 2755 (2018).","journal-title":"Nat. Commun."},{"key":"1391_CR120","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/art.41516","volume":"73","author":"W Tao","year":"2021","unstructured":"Tao, W. et al. Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 73, 212\u2013222 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1391_CR121","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40744-021-00330-y","volume":"8","author":"S Cohen","year":"2021","unstructured":"Cohen, S. et al. A molecular signature response classifier to predict inadequate response to tumor necrosis factor-\u03b1 inhibitors: the network-004 prospective observational study. Rheumatol. Ther. 8, 1159\u20131176 (2021).","journal-title":"Rheumatol. Ther."},{"key":"1391_CR122","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2665-9913(21)00224-1","volume":"3","author":"JM Maassen","year":"2021","unstructured":"Maassen, J. M., van Ouwerkerk, L. & Allaart, C. F. Tapering of disease-modifying antirheumatic drugs: an overview for daily practice. Lancet Rheumatol. 3, e659\u2013e670 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1391_CR123","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13075-019-2064-y","volume":"21","author":"EC de Moel","year":"2019","unstructured":"de Moel, E. C. et al. Circulating calprotectin (S100A8\/A9) is higher in rheumatoid arthritis patients that relapse within 12\u2009months of tapering anti-rheumatic drugs. Arthritis Res. Ther. 21, 268 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR124","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1136\/annrheumdis-2015-207900","volume":"75","author":"J Rech","year":"2016","unstructured":"Rech, J. et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann. Rheum. Dis. 75, 1637\u20131644 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR125","first-page":"126","volume":"41","author":"HL Gul","year":"2023","unstructured":"Gul, H. L. et al. Can biomarkers predict successful tapering of conventional disease-modifying therapy in rheumatoid arthritis patients in stable remission? Clin. Exp. Rheumatol. 41, 126\u2013136 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1391_CR126","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/art.24661","volume":"60","author":"D van der Woude","year":"2009","unstructured":"van der Woude, D. et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 60, 2262\u20132271 (2009).","journal-title":"Arthritis Rheum."},{"key":"1391_CR127","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-092478","volume":"15","author":"F Rayner","year":"2025","unstructured":"Rayner, F. et al. Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study. BMJ Open. 15, e092478 (2025).","journal-title":"BMJ Open."},{"key":"1391_CR128","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1136\/annrheumdis-2018-213217","volume":"77","author":"G Filippou","year":"2018","unstructured":"Filippou, G. et al. The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology group for ultrasound: the STARTER study. Ann. Rheum. Dis. 77, 1283\u20131289 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR129","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2011-200548","volume":"71","author":"B Saleem","year":"2012","unstructured":"Saleem, B. et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann. Rheum. Dis. 71, 1316\u20131321 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR130","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3899\/jrheum.160193","volume":"43","author":"J Han","year":"2016","unstructured":"Han, J., Geng, Y., Deng, X. & Zhang, Z. Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission: a systematic review and metaanalysis. J. Rheumatol. 43, 2010\u20132018 (2016).","journal-title":"J. Rheumatol."},{"key":"1391_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15141753","volume":"15","author":"Z Batalov","year":"2025","unstructured":"Batalov, Z., Sapundzhieva, T., Batalov, K., Karalilova, R. & Batalov, A. The role of musculoskeletal ultrasound in biologic drug tapering and relapse monitoring: findings from a one-year prospective study in a cohort of rheumatoid arthritis patients in sustained clinical remission. Diagnostics 15, 1753\u00a0https:\/\/doi.org\/10.3390\/diagnostics15141753 (2025).","journal-title":"Diagnostics"},{"key":"1391_CR132","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","volume":"79","author":"P Emery","year":"2020","unstructured":"Emery, P. et al. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann. Rheum. Dis. 79, 1023\u20131030 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1553-8","volume":"20","author":"LE Burgers","year":"2018","unstructured":"Burgers, L. E., Boeters, D. M., Reijnierse, M. & van der Helm-van Mil, A. H. M. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study. Arthritis Res. Ther. 20, 68 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02735-8","volume":"24","author":"HA Ahmad","year":"2022","unstructured":"Ahmad, H. A. et al. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. Arthritis Res. Ther. 24, 47 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR135","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","volume":"82","author":"CLM Krieckaert","year":"2023","unstructured":"Krieckaert, C. L. M. et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 82, 65\u201373 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR136","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kev298","volume":"55","author":"D-Y Chen","year":"2015","unstructured":"Chen, D.-Y. et al. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology 55, 143\u2013148 (2015).","journal-title":"Rheumatology"},{"key":"1391_CR137","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/17425255.2017.1320390","volume":"13","author":"C Bouman","year":"2017","unstructured":"Bouman, C. et al. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. Expert Opin. Drug Metab. Toxicol. 13, 597\u2013604 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1391_CR138","doi-asserted-by":"publisher","first-page":"e2323098","DOI":"10.1001\/jamanetworkopen.2023.23098","volume":"6","author":"S Bitoun","year":"2023","unstructured":"Bitoun, S. et al. Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Netw. Open 6, e2323098\u2013e2323098 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1391_CR139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann. Rheum. Dis. 76, 17\u201328 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR140","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.autrev.2016.07.026","volume":"15","author":"R Lopez-Mejias","year":"2016","unstructured":"Lopez-Mejias, R. et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun. Rev. 15, 1013\u20131030 (2016).","journal-title":"Autoimmun. Rev."},{"key":"1391_CR141","volume":"15","author":"SR Borra","year":"2023","unstructured":"Borra, S. R., Panjiyar, B. K., Panicker, S. S. & Danduboyina, A. Role of cardiac biomarkers in the evaluation of rheumatoid arthritis: a systematic review. Cureus 15, e47416 (2023).","journal-title":"Cureus"},{"key":"1391_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-025-02198-8","volume":"27","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri, L., Duggal, S., Aparece, J. P. & Sairam, S. Cardiovascular risk factor and atherosclerosis in rheumatoid arthritis (RA). Curr. Cardiol. Rep. 27, 31 (2025).","journal-title":"Curr. Cardiol. Rep."},{"key":"1391_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040870","volume":"13","author":"A Pamies","year":"2025","unstructured":"Pamies, A., Vallve, J. C. & Paredes, S. New cardiovascular risk biomarkers in rheumatoid arthritis: implications and clinical utility-a narrative review. Biomedicines 13, 870\u00a0https:\/\/doi.org\/10.3390\/biomedicines13040870 (2025).","journal-title":"Biomedicines"},{"key":"1391_CR144","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032095","volume":"13","author":"DH Solomon","year":"2024","unstructured":"Solomon, D. H. et al. Biomarkers of cardiovascular risk in patients with rheumatoid arthritis: results from the TARGET trial. J. Am. Heart Assoc. 13, e032095 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1391_CR145","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.clim.2018.12.011","volume":"199","author":"E Balogh","year":"2018","unstructured":"Balogh, E. et al. Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. Clin. Immunol. 199, 47\u201351\u00a0https:\/\/doi.org\/10.1016\/j.clim.2018.12.011 (2018).","journal-title":"Clin. Immunol."},{"key":"1391_CR146","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.autrev.2016.03.014","volume":"15","author":"Z Szekanecz","year":"2016","unstructured":"Szekanecz, Z. et al. Autoimmune atherosclerosis in 3D: how it develops, how to diagnose and what to do. Autoimmun. Rev. 15, 756\u2013769 (2016).","journal-title":"Autoimmun. Rev."},{"key":"1391_CR147","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12016-012-8346-7","volume":"45","author":"J Kurko","year":"2013","unstructured":"Kurko, J. et al. Genetics of rheumatoid arthritis \u2014 a comprehensive review. Clin. Rev. Allergy Immunol. 45, 170\u2013179 (2013).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1391_CR148","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.tig.2012.03.001","volume":"28","author":"AJ Lusis","year":"2012","unstructured":"Lusis, A. J. Genetics of atherosclerosis. Trends Genet. 28, 267\u2013275 (2012).","journal-title":"Trends Genet."},{"key":"1391_CR149","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/art.37961","volume":"65","author":"J Sokolove","year":"2013","unstructured":"Sokolove, J. et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 65, 1719\u20131724 (2013).","journal-title":"Arthritis Rheum."},{"key":"1391_CR150","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1136\/annrheumdis-2015-208579","volume":"75","author":"S Ajeganova","year":"2016","unstructured":"Ajeganova, S. et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann. Rheum. Dis. 75, 1924\u20131932 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1563-8","volume":"18","author":"FR Spinelli","year":"2017","unstructured":"Spinelli, F. R. et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMC Musculoskelet. Disord. 18, 214 (2017).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1391_CR152","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1196\/annals.1361.071","volume":"1051","author":"Y Sherer","year":"2005","unstructured":"Sherer, Y. et al. Prevalence of antiphospholipid and antioxidized low-density lipoprotein antibodies in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1051, 299\u2013303 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1391_CR153","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","volume":"51","author":"JE Pope","year":"2021","unstructured":"Pope, J. E. & Choy, E. H. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin. Arthritis Rheum. 51, 219\u2013229 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1391_CR154","volume":"17","author":"FH Shah","year":"2025","unstructured":"Shah, F. H., Agrawal, S., Tated, R. C., Maheta, D. & Naqvi, S. Novel biomarkers and advanced imaging in cardiovascular risk stratification for rheumatic diseases. Cureus 17, e89794 (2025).","journal-title":"Cureus"},{"key":"1391_CR155","first-page":"398","volume":"35","author":"G Kerekes","year":"2008","unstructured":"Kerekes, G. et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398\u2013406 (2008).","journal-title":"J. Rheumatol."},{"key":"1391_CR156","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","volume":"53","author":"E Choy","year":"2014","unstructured":"Choy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z. & Nurmohamed, M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology 53, 2143\u20132154 (2014).","journal-title":"Rheumatology"},{"key":"1391_CR157","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes, I. B. et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis. 74, 694\u2013702 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR158","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","volume":"162","author":"PM Ridker","year":"2011","unstructured":"Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am. Heart J. 162, 597\u2013605 (2011).","journal-title":"Am. Heart J."},{"key":"1391_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00891-0","volume":"14","author":"M Mossmann","year":"2022","unstructured":"Mossmann, M. et al. Increased serum IL-6 is predictive of long-term cardiovascular events in high-risk patients submitted to coronary angiography: an observational study. Diabetol. Metab. Syndr. 14, 125 (2022).","journal-title":"Diabetol. Metab. Syndr."},{"key":"1391_CR160","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","volume":"10","author":"G Kerekes","year":"2014","unstructured":"Kerekes, G. et al. Rheumatoid arthritis and metabolic syndrome. Nat. Rev. Rheumatol. 10, 691\u2013696 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR161","doi-asserted-by":"publisher","first-page":"710928","DOI":"10.1155\/2013\/710928","volume":"2013","author":"I Ferraz-Amaro","year":"2013","unstructured":"Ferraz-Amaro, I., Gonzalez-Juanatey, C., Lopez-Mejias, R., Riancho-Zarrabeitia, L. & Gonzalez-Gay, M. A. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm. 2013, 710928 (2013).","journal-title":"Mediators Inflamm."},{"key":"1391_CR162","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","volume":"9","author":"J Robertson","year":"2013","unstructured":"Robertson, J., Peters, M. J., McInnes, I. B. & Sattar, N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat. Rev. Rheumatol. 9, 513\u2013523 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR163","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bcp.2019.03.030","volume":"165","author":"V Francisco","year":"2019","unstructured":"Francisco, V. et al. Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases. Biochem. Pharmacol. 165, 196\u2013206 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"1391_CR164","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","volume":"7","author":"R Gomez","year":"2011","unstructured":"Gomez, R. et al. What\u2019s new in our understanding of the role of adipokines in rheumatic diseases? Nat. Rev. Rheumatol. 7, 528\u2013536 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR165","first-page":"1183","volume":"20","author":"A Hassan","year":"2020","unstructured":"Hassan, A., Ahmad, D. N. A. & Hasan, E. J. Leptin\/adiponectin ratio a risk factor for cardiovascular disease in early rheumatoid arthritis women. Biochem. Cell Arch. 20, 1183\u20131185 (2020).","journal-title":"Biochem. Cell Arch."},{"key":"1391_CR166","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3899\/jrheum.140122","volume":"41","author":"PH Dessein","year":"2014","unstructured":"Dessein, P. H., Tsang, L., Woodiwiss, A. J., Norton, G. R. & Solomon, A. Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis. J. Rheumatol. 41, 1746\u20131754 (2014).","journal-title":"J. Rheumatol."},{"key":"1391_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/ar4384","volume":"15","author":"Y Kang","year":"2013","unstructured":"Kang, Y. et al. Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res. Ther. 15, R194 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR168","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/21623945.2017.1402151","volume":"7","author":"G Fruhbeck","year":"2018","unstructured":"Fruhbeck, G., Catalan, V., Rodriguez, A. & Gomez-Ambrosi, J. Adiponectin-leptin ratio: a promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte 7, 57\u201362 (2018).","journal-title":"Adipocyte"},{"key":"1391_CR169","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrrheum.2012.16","volume":"8","author":"G Kerekes","year":"2012","unstructured":"Kerekes, G. et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat. Rev. Rheumatol. 8, 224\u2013234 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR170","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001804","volume":"7","author":"A Hamar","year":"2021","unstructured":"Hamar, A. et al. Prospective, simultaneous assessment of joint and vascular inflammation by PET\/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status. RMD Open 7, e001804\u00a0https:\/\/doi.org\/10.1136\/rmdopen-2021-001804 (2021).","journal-title":"RMD Open"},{"key":"1391_CR171","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/rheumatology\/keae242","volume":"64","author":"JT Giles","year":"2025","unstructured":"Giles, J. T. et al. Association of the multi-biomarker disease activity score with arterial 18-fluorodeoxyglucose uptake in rheumatoid arthritis. Rheumatology 64, 1077\u20131083 (2025).","journal-title":"Rheumatology"},{"key":"1391_CR172","volume":"29","author":"H Rudolf","year":"2020","unstructured":"Rudolf, H. et al. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: the getABI-study. Int. J. Cardiol. Heart Vasc. 29, 100553 (2020).","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"1391_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455346","volume":"15","author":"L Guo","year":"2024","unstructured":"Guo, L., Wang, J., Li, J., Yao, J. & Zhao, H. Biomarkers of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Front. Immunol. 15, 1455346 (2024).","journal-title":"Front. Immunol."},{"key":"1391_CR174","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.semarthrit.2020.01.006","volume":"50","author":"M Elhai","year":"2020","unstructured":"Elhai, M., Avouac, J. & Allanore, Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: where do we stand? Semin. Arthritis Rheum. 50, 480\u2013491 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1391_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1056121","volume":"9","author":"V Pulito-Cueto","year":"2022","unstructured":"Pulito-Cueto, V. et al. Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis. Front. Mol. Biosci. 9, 1056121 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"1391_CR176","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2019-216709","volume":"79","author":"R Castellanos-Moreira","year":"2020","unstructured":"Castellanos-Moreira, R. et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann. Rheum. Dis. 79, 587\u2013594 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR177","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1136\/annrheumdis-2013-203510","volume":"72","author":"C Turesson","year":"2013","unstructured":"Turesson, C., Mathsson, L., Jacobsson, L. T. H., Sturfelt, G. & R\u00f6nnelid, J. Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann. Rheum. Dis. 72, 2047\u20132048 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR178","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.2025-0390.PV204","volume":"52","author":"SH Chang","year":"2025","unstructured":"Chang, S. H. et al. Serum biomarkers of pulmonary damage and risk for progression of rheumatoid arthritis-associated interstitial lung disease. J. Rheumatol. 52, 323\u2013333 (2025).","journal-title":"J. Rheumatol."},{"key":"1391_CR179","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41584-022-00764-w","volume":"18","author":"B Soos","year":"2022","unstructured":"Soos, B. et al. Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. Nat. Rev. Rheumatol. 18, 249\u2013257 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1391_CR180","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1080\/14656566.2020.1787381","volume":"21","author":"HG Raterman","year":"2020","unstructured":"Raterman, H. G., Bultink, I. E. & Lems, W. F. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention. Expert Opin. Pharmacother. 21, 1725\u20131737 (2020).","journal-title":"Expert Opin. Pharmacother."},{"key":"1391_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1805-7","volume":"21","author":"Z Szekanecz","year":"2019","unstructured":"Szekanecz, Z., Raterman, H. G., Petho, Z. & Lems, W. F. Common mechanisms and holistic care in atherosclerosis and osteoporosis. Arthritis Res. Ther. 21, 15 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1391_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102658","volume":"19","author":"Z Szekanecz","year":"2020","unstructured":"Szekanecz, Z. et al. Eight pillars of oncorheumatology: crossroads between malignancies and musculoskeletal diseases. Autoimmun. Rev. 19, 102658 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1391_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050648","volume":"15","author":"E Sebestyen","year":"2025","unstructured":"Sebestyen, E. et al. Effects of tofacitinib therapy on circulating tumour-associated antigens and their relationship with clinical, laboratory and vascular parameters in rheumatoid arthritis. Biomolecules 15, 648\u00a0https:\/\/doi.org\/10.3390\/biom15050648 (2025).","journal-title":"Biomolecules"},{"key":"1391_CR184","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225982","author":"E Sebbag","year":"2024","unstructured":"Sebbag, E. et al. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/ard-2024-225982 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1391_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99071-9","volume":"11","author":"A Pusztai","year":"2021","unstructured":"Pusztai, A. et al. Associations of vascular and bone status in arthritis patients. Sci. Rep. 11, 19504 (2021).","journal-title":"Sci. Rep."},{"key":"1391_CR186","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaccao.2020.12.003","volume":"3","author":"ES Lau","year":"2021","unstructured":"Lau, E. S. et al. Cardiovascular risk factors are associated with future cancer. JACC CardioOncol. 3, 48\u201358 (2021).","journal-title":"JACC CardioOncol."},{"key":"1391_CR187","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/acr.21767","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis, J. R. et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 64, 1794\u20131803 (2012).","journal-title":"Arthritis Care Res."},{"key":"1391_CR188","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05756-5","volume":"45","author":"E Tiwari","year":"2025","unstructured":"Tiwari, E. et al. Artificial intelligence-based cardiovascular\/stroke risk stratification in women affected by autoimmune disorders: a narrative survey. Rheumatol. Int. 45, 14 (2025).","journal-title":"Rheumatol. Int."}],"updated-by":[{"DOI":"10.1038\/s41584-026-01430-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01391-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:03:01Z","timestamp":1787580181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01391-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":188,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01391-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"15 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41584-026-01430-1","URL":"https:\/\/doi.org\/10.1038\/s41584-026-01430-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}